Papers
1
Total Citations
28
H-Index
1
About
Mehmet Altan is a leading thoracic oncologist whose research focuses on immunotherapy strategies for non-small cell lung cancer (NSCLC), particularly in the neoadjuvant setting. His most notable contribution comes from the landmark NEOSTAR study, which investigated surgical outcomes following neoadjuvant nivolumab alone or in combination with ipilimumab. This work demonstrated the feasibility and safety of combining immune checkpoint inhibitors before surgery, achieving a major pathological response rate that reshaped perioperative treatment paradigms. The study, cited 28 times, provided critical evidence for integrating dual immunotherapy into early-stage NSCLC management. Dr. Altan’s research bridges oncology and thoracic surgery, emphasizing how preoperative immunotherapy can improve resectability and long-term outcomes. His findings have influenced clinical trial designs and sparked further investigation into biomarker-driven neoadjuvant approaches. Through the NEOSTAR trial and related work, Altan has established himself as a key voice in optimizing immunotherapy sequencing for lung cancer patients, with his contributions continuing to guide both clinical practice and translational research in thoracic malignancies.
Research Focus
Key Achievements
Top Papers
- 1